Inflammatix, Inc.

Inflammatix, Inc. is a U.S.-based startup that is revolutionizing diagnostics through its innovative approach of tapping into the immune system. Founded in 2016, the company's mission is reflected in its slogan "We're reimagining diagnostics by reading the immune system." Inflammatix is focused on developing a pioneering point-of-care instrument platform that works in conjunction with a test to facilitate the diagnosis of acute infection and sepsis by leveraging advanced immune response diagnostics. This breakthrough technology is designed to rapidly provide clinicians with crucial information about the likelihood of bacterial or viral infection, as well as the necessity for ICU level care in emergency departments. The faster results delivered by the platform have the potential to lead to more prompt and suitable therapy, as well as decisions regarding the level of care required. In November 2021, the company received a significant grant investment of $1.70M from the National Institutes of Health. It's important to note that the products developed by Inflammatix are still in the developmental phase and have not yet received marketing approval or regulatory clearance in any jurisdiction. With its focus on big data, biotechnology, and healthcare, Inflammatix is poised to continue making strides in the field of diagnostics and providing critical solutions for acute infections and sepsis.